ATL001

Unassigned

New Medicines

Metastatic or recurrent malignant melanoma

Information

Achilles Therapeutics
Achilles Therapeutics

Development and Regulatory status

Phase II Clinical Trials
None
None

Category

Personalised T cell immunotherapy targeting clonal/truncal tumour neoantigens: protein markers unique to the individual that are expressed on the surface of every cancer cell. Achilles uses DNA sequencing data from each patient.
In 2011, the UK age-standardised incidence of melanoma for females was 17.6 (11.7 in 2001) and for males 17.5 (10.1 in 2001) per 100,000 population [1].
Metastatic or recurrent malignant melanoma
Intravenous infusion

Trial or other data

Aug 19 · Achilles Therapeutics initiates a PI/II trial to characterise the safety and clinical activity of ATL001 administered intravenously in adults with metastatic or recurrent melanoma (NCT03997474; ATX-ME001). The open-label trial is enrolling 20 patients in the UK (sites are the Christie Hospital Manchester and Freeman Hospital Newcastle). The trial is due to complete Oct 22 [2].

Advanced non-small cell lung cancer (NSCLC)

Information

Advanced therapy medicinal product (ATMP)
Achilles Therapeutics
Achilles Therapeutics

Development and Regulatory status

Phase II Clinical Trials
None
None

Category

Personalised T cell immunotherapy targeting clonal/truncal tumour neoantigens: protein markers unique to the individual that are expressed on the surface of every cancer cell. Achilles uses DNA sequencing data from each patient.
In 2016, approximately 32,500 people were diagnosed with NSCLC in England, and 85-90% are non-small cell lung cancers (NSCLC) [1].
Advanced non-small cell lung cancer (NSCLC)
Intravenous infusion

Trial or other data

Jan 20 · PI/II study (NCT04032847) is recruiting [2].
Jul 19 · Achilles Therapeutics initiates a first-in-human PI/II trial to evaluate the safety and clinical activity of ATL001 in patients with advanced NSCLC (ATX-NS001; NCT04032847). The open-label trial is enrolling 50 adults in the UK (sites include UCLH, Freeman Hospital in Newcastle, University Hospital Birmingham, Cambridge University Hospital, The Christie Hospital and University Hospital Southampton. Collection of primary outcome safety data is due to complete Jul 23, and the trial to complete Dec 23 [2].